Literature DB >> 23584291

Further advances in genetically informed lung cancer medicine.

Caroline Nebhan, William Pao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23584291      PMCID： PMC3640560          DOI： 10.1097/JTO.0b013e31828f583c

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  24 in total

1.  A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.

Authors:  Oliver Gautschi; Chantal Pauli; Klaus Strobel; Astrid Hirschmann; Gert Printzen; Stefan Aebi; Joachim Diebold
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

Review 2.  RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.

Authors:  Raffaele Ciampi; Yuri E Nikiforov
Journal:  Endocrinology       Date:  2006-08-31       Impact factor: 4.736

3.  Activation of a novel human transforming gene, ret, by DNA rearrangement.

Authors:  M Takahashi; J Ritz; G M Cooper
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

4.  KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.

Authors:  Weijing Cai; Chunxia Su; Xuefei Li; Lihong Fan; Limou Zheng; Ke Fei; Caicun Zhou
Journal:  Cancer       Date:  2013-02-01       Impact factor: 6.860

5.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman
Journal:  Lancet       Date:  2012-06-25       Impact factor: 79.321

6.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

Authors:  H Donis-Keller; S Dou; D Chi; K M Carlson; K Toshima; T C Lairmore; J R Howe; J F Moley; P Goodfellow; S A Wells
Journal:  Hum Mol Genet       Date:  1993-07       Impact factor: 6.150

7.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

Review 8.  New therapeutic approaches to treat medullary thyroid carcinoma.

Authors:  Martin Schlumberger; Francesca Carlomagno; Eric Baudin; Jean Michel Bidart; Massimo Santoro
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-01

9.  Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.

Authors:  Francesca Carlomagno; Teresa Guida; Suresh Anaganti; Giancarlo Vecchio; Alfredo Fusco; Anderson J Ryan; Marc Billaud; Massimo Santoro
Journal:  Oncogene       Date:  2004-08-12       Impact factor: 9.867

10.  Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.

Authors:  Daisuke Matsubara; Yoshihiko Kanai; Shumpei Ishikawa; Shiori Ohara; Taichiro Yoshimoto; Takashi Sakatani; Sachiko Oguni; Tomoko Tamura; Hiroaki Kataoka; Shunsuke Endo; Yoshinori Murakami; Hiroyuki Aburatani; Masashi Fukayama; Toshiro Niki
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609
View more
  3 in total

1.  Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines.

Authors:  David Cl Lam; Susan Y Luo; Wen Deng; Johnny Sh Kwan; Jaime Rodriguez-Canales; Annie Lm Cheung; Grace Hw Cheng; Chi-Ho Lin; Ignacio I Wistuba; Pak C Sham; Thomas Sk Wan; Sai-Wah Tsao
Journal:  Onco Targets Ther       Date:  2015-01-16       Impact factor: 4.147

Review 2.  Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond.

Authors:  Christopher Delaney; Samuel Frank; R Stephanie Huang
Journal:  Chin J Cancer       Date:  2015-04-08

3.  Ret finger protein-like 3 promotes tumor cell growth by activating telomerase reverse transcriptase expression in human lung cancer cells.

Authors:  Wangbing Chen; Jianjun Lu; Yu Qin; Jingshu Wang; Yun Tian; Dingbo Shi; Shusen Wang; Yao Xiao; Meng Dai; Lu Liu; Guo Wei; Taihua Wu; Bilian Jin; Xiangsheng Xiao; Tie-Bang Kang; Wenlin Huang; Wuguo Deng
Journal:  Oncotarget       Date:  2014-12-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.